AraC-based pharmacotherapy of chronic myeloid leukaemia

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 7, 2001, Pages 1129-1135

  Reiter, A ^a   Hochhaus, A ^a   Berger, U ^a   Kuh, C ^a   Hehlmann, R ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

AraC; Chronic myeloid leukaemia; Chronic phase; Interferon

Indexed keywords

ALPHA INTERFERON; CYTARABINE; CYTARABINE 5' STEARYLPHOSPHATE; HOMOHARRINGTONINE; IMATINIB; RETINOIC ACID;

BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; METAPHASE CHROMOSOME; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROTOXICITY; PHILADELPHIA 1 CHROMOSOME; REVIEW; THROMBOCYTOPENIA; WEIGHT REDUCTION;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOTIDES; CLINICAL TRIALS; CYTARABINE; CYTIDINE MONOPHOSPHATE; DRUG ADMINISTRATION SCHEDULE; GUIDELINES; HUMANS; INTERFERONS; LEUKEMIA, MYELOID, CHRONIC; SURVIVAL ANALYSIS;

EID: 0034946326     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.7.1129     Document Type: Review

References (46)

1. Interferon alfa versus chemotherapy for chronic myeloid leukemia: A meta-analysis of seven randomized trials
2. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology
3. Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score
4. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa
5. Prognosis of patients with CML: Updated results of the collaborative CML prognostic factors group
6. Complete cytogenetic responders and long term survivors
7. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
8. Clinical pharmacology of intermediate and low-dose cytosine arabinoside (ara-C) therapy in patients with hematologic malignancies
9. Efficacy and toxicity of IFN-alpha2b combined with cytarabine in chronic myelogenous leukaemia
10. Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemia
11. Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia
12. Interferon protects normal human granulocyte/macrophage colony-forming cells from Ara-C cytotoxicity
13. Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low dose cytarabine
14. Cytogenetic remission in chronic myelogenous leukemia using interferon α2a and hydroxyurea with or without low-dose cytosine-arabinoside
15. Treatment of 11 patients with chronic myelogenous leukemia with interferon-alpha-2C and low-dose cytosine arabinoside
16. Combined interferon alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia
17. Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: Results of the Austrian multi-center Phase II study
18. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-α and low dose cytarabine
19. Interferon-alpha plus low-dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patients
20. The treatment of chronic myelogenous leukemia by interferon and cystosine-arabinoside: Rational and design of the French trials
21. Cytarabine increases karyotypic response and survival in IFNa treated chronic myelogenous leukemia patients
22. A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia
23. The use of interferon-a with or without cytarabine and other new agents for the treatment of chronic myeloid leukemia
24. Interferon-α and Ara-C
25. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine
26. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia
27. PEG-Interferon α-2A (Pegasys™) with or without cytarabine in patients with relapsed or refractory chronic phase CML
28. Efficiacy of an ABL tyrosine kinase inhibitor in conjunction with other anti-neoplastic agents against BCR-ABL positive cells
29. Synergistic activity of STI571 with chemotherapeutic drugs and irradiation
30. In vitro effects of STI571-containing drug combinations on growth of Ph-positive myelogenous leukemia-derived cells
31. Phase II study of STI571, a tyrosine kinase inhibitor, in patients (pts.) with resistant or refractory Philadelphia-chromosome positive chronic myeloid leukemia (Ph+CML)
32. A Phase II study to determine the safety and antileukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis
33. A Phase II study of STI571 in adult patients with Philadelphia-chromosome positive chronic myeloid leukemia in accelerated phase
34. Effect of retinoic acid and interferon alpha on granulocyte-macrophage colony forming cells in chronic myeloid leukemia: Increased inhibition by all-trans- and 13-cis-retinoic acids in advanced stage disease
35. All-trans retinoic acid combined with interferon-alpha effectively inhibits granulocyte-macrophage colony formation in chronic myeloid leukemia
36. All-trans retinoic acid potentiates the inhibitory effects of interferon alpha on chronic myeloid leukemia progenistors in vitro
37. Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia
38. Pilot study of combined therapy with interferon-alpha, arabinosyl cytosine and all-trans retinoic acid in patients with chronic myeloid leukemia in the chronic phase
39. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5′-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine
40. Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma-phase I/II studies and pharmacokinetics
41. A Phase II study to assess efficacy and safety of Interferon alpha 2b (IFN) in combination with oral cytarabine ocfosfate (YNK01) in patients with chronic myelogenous leukemia (CML)
42. Interferon plus oral Ara-C in chronic myeloid leukemia primarily resistant or with minimal cytogenetic response to Interferon
43. Preliminary report on the CML-GIII-1/97 protocol for the treatment of chronic myelogenous leukaemia (CML) with interferon (IFN) and the per os Ara-C derivative YNK01 plus hydroxyurea (HU)
44. Treatment of patients with advanced chronic myelogenous leukemia with interferon-alpha-2b and continuous oral cytarabine ocfosfate (YNK01): A pilot study
45. A Phase II study of interferon alpha (IFN) and intermittent oral cytarabine (YNK01) in the treatment of newly diagnosed chronic myeloid leukemia (CML)
46. IFN and YNK01: Results of a ICSG on CML protocol